3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
Dexamethasone
129
Lenalidomide
70
Cyclophosphamide
70
Bortezomib
69
Calcium Dobesilate
50
fludarabine
44
pomalidomide
40
daratumumab
37
carfilzomib
33
fludarabine phosphate
31
Melphalan
25
dexamethasone acetate
20
dexamethasone 21-phosphate
20
auricularum
18
Filgrastim
18
Whole-Body Irradiation
14
Biopsy
13
isatuximab
12
Vorinostat
12
Tacrolimus
12
Peripheral Blood Stem Cell Transplantation
12
Magnetic Resonance Spectroscopy
12
Granulocyte Colony-Stimulating Factor
12
Specimen Handling
11
Sirolimus
11
ixazomib
10
belantamab mafodotin
10
Panobinostat
10
Mycophenolic Acid
10
Cyclosporine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Multiple Myeloma
×
zimberelimab
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled